Literature DB >> 17035246

Identification of susceptibility loci for cervical carcinoma by genome scan of affected sib-pairs.

Malin T Engelmark1, Emma L Ivansson, Jessica J Magnusson, Inger M Gustavsson, Anna H Beskow, Patrik K E Magnusson, Ulf B Gyllensten.   

Abstract

Cervical cancer is caused by a combination of environmental and genetic risk factors. Infection by oncogenic types of human papillomavirus is recognized as the major environmental risk factor and epidemiological studies indicate that host genetic factors predispose to disease development. A number of genetic susceptibility factors have been proposed, but with exception of the human leukocyte antigen CHLA, class II, have not shown consistent results among studies. We have performed the first genomewide linkage scan using 278 affected sib-pairs to identify loci involved in susceptibility to cervical cancer. A two-step qualitative non-parametric linkage analysis using 387 microsatellites with an average spacing of 10.5 cM revealed excess allelic sharing at nine regions on eight chromosomes. These regions were further analysed with 125 markers to increase the map density to 1.28 cM. Nominal significant linkage was found for three of the nine loci [9q32 (maximum lod-score, MLS) =1.95, P<0.002), 12q24 (MLS=1.25, P<0.015) and 16q24 (MLS=1.35, P<0.012)]. These three regions have previously been connected to human cancers that share characteristics with cervical carcinoma, such as esophageal cancer and Hodgkin's lymphoma. A number of candidate genes involved in defence against viral infections, immune response and tumour suppression are found in these regions. One such gene is the thymic stromal co-transporter (TSCOT). Analyses of TSCOT single nucleotide polymorphisms further strengthen the linkage to this region (MLS=2.40, P<0.001). We propose that the 9q32 region contains susceptibility locus for cervical cancer and that TSCOT is a candidate gene potentially involved in the genetic predisposition to this disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17035246     DOI: 10.1093/hmg/ddl411

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  6 in total

1.  SNP frequency estimation using massively parallel sequencing of pooled DNA.

Authors:  Max Ingman; Ulf Gyllensten
Journal:  Eur J Hum Genet       Date:  2008-10-15       Impact factor: 4.246

2.  Cervical cancer-associated promoter polymorphism affects akna expression levels.

Authors:  G A Martínez-Nava; K Torres-Poveda; A Lagunas-Martínez; M Bahena-Román; M A Zurita-Díaz; E Ortíz-Flores; A García-Carrancá; V Madrid-Marina; A I Burguete-García
Journal:  Genes Immun       Date:  2014-11-06       Impact factor: 2.676

3.  The zinc finger protein ZNF268 is overexpressed in human cervical cancer and contributes to tumorigenesis via enhancing NF-κB signaling.

Authors:  Wei Wang; Mingxiong Guo; Li Hu; Jinyang Cai; Yan Zeng; Jun Luo; Zhiqiang Shu; Wenxin Li; Zan Huang
Journal:  J Biol Chem       Date:  2012-10-22       Impact factor: 5.157

4.  Polymorphisms in 9q32 and TSCOT are linked to cervical cancer in affected sib-pairs with high mean age at diagnosis.

Authors:  Malin T Engelmark; Emma L Ivansson; Jessica J Magnusson; Inger M Gustavsson; Per-Ivan Wyöni; Max Ingman; Patrik K E Magnusson; Ulf B Gyllensten
Journal:  Hum Genet       Date:  2008-04-08       Impact factor: 4.132

5.  Genetic studies on the APOA1-C3-A5 gene cluster in Asian Indians with premature coronary artery disease.

Authors:  Jayashree Shanker; Ganapathy Perumal; Veena S Rao; Natesha B Khadrinarasimhiah; Shibu John; Sridhara Hebbagodi; Manjari Mukherjee; Vijay V Kakkar
Journal:  Lipids Health Dis       Date:  2008-09-19       Impact factor: 3.876

6.  Expression Analyses Revealed Thymic Stromal Co-Transporter/Slc46A2 Is in Stem Cell Populations and Is a Putative Tumor Suppressor.

Authors:  Ki Yeon Kim; Gwanghee Lee; Minsang Yoon; Eun Hye Cho; Chan-Sik Park; Moon Gyo Kim
Journal:  Mol Cells       Date:  2015-05-27       Impact factor: 5.034

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.